Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Mudaliar, Manikhandan A. V.; Haggart, Ross D.; Miele, Gino; Sellar, Grant; Tan, Karen; Goodlad, John; Milne, Elspeth; Vail, David M.; Kurzman, Ilene; Crowther, Daniel; Argyle, David J. (2013)
Publisher: Public Library of Science (PLoS)
Languages: English
Types: Article

Classified by OpenAIRE into

mesheuropmc: hemic and lymphatic diseases, immune system diseases

We present the first comparison of global transcriptional changes in canine and human diffuse large B-cell lymphoma (DLBCL), with particular reference to the nuclear factor-kappa B (NF-kappa'B) pathway. Microarray data generated from canine DLBCL and normal lymph nodes were used for differential expression, co-expression and pathway analyses, and compared with analysis of microarray data from human healthy and DLBCL lymph nodes. The comparisons at gene level were performed by mapping the probesets in canine microarrays to orthologous genes in humans and vice versa. A considerable number of differentially expressed genes between canine lymphoma and healthy lymph node samples were also found differentially expressed between human DLBCL and healthy lymph node samples. Principal component analysis using a literature-derived NF-kappa B target gene set mapped to orthologous canine array probesets and human array probesets clearly separated the healthy and cancer samples in both datasets. The analysis demonstrated that for both human and canine DLBCL there is activation of the NF-kappa B/p65 canonical pathway, indicating that canine lymphoma could be used as a model to study NF-kappa B-targeted therapeutics for human lymphoma. To validate this, tissue arrays were generated for canine and human NHL and immunohistochemistry was employed to assess NF-kappa B activation status. In addition, human and canine B-cell lymphoma lines were assessed for NF-kB activity and the effects of NF-kappa B inhibition.

  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Gordon I, Paoloni M, Mazcko C, Khanna C (2009) The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med.; 6(10): e1000161.
    • 2. Adams VJ, Evans KM, Sampson J, Wood JL (2010). Methods and mortality results of a health survey of purebred dogs in the UK. J Small Anim Pract.; 51(10): 512-24.
    • 3. Shearin AL, Ostrander EA (2010) Leading the way: canine models of genomics and disease. Disease models & mechanisms.; 3(1-2): 27-34.
    • 4. Paoloni M, Khanna C (2008) Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer.; 8(2): 147-56.
    • 5. Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, et al (2009) Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics.; 10: 135.
    • 6. Cancer statistics registrations (2010) Available at: http://www.ons.gov.uk/ons/ rel/vsob1/cancer-registrations-in-england/2010/2010-cancer-registrations-inengland-statistical-bulletin-2.html (Accessed August 2013).
    • 7. Cancer Incidence in Wales 2003-2007 (2009) Available at: http://www.wales.nhs. uk/sites3/Documents/242/Cancer%20Incidence%20in%20Wales%202003- 2007.pdf (Accessed August 2013).
    • 8. Cancer incidence in Scotland (2013) Available at: http://www.isdscotland.org/ Health-Topics/Cancer/ (Accessed August 2013).
    • 9. Vail DM, Young KM (2007) Canine Lymphoma and Lymphoid Leukemia. In:. Withrow and MacEwen's small animal clinical oncology, Withrow SJ, Vail DM, (ed) 4ed. London/GB: Elsevier Health Sciences; 2007. p. 699-700.
    • 10. Chan WJ (2010) Pathogenesis of diffuse large B cell lymphoma. Int J Hematol. 92(2): 219-30.
    • 11. Vallabhapurapu S, Karin M (2009) Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol.; 27: 693-733.
    • 12. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature.; 403(6769): 503-11.
    • 13. Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S, et al (2005) Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood.; 106(5): 1770-7.
    • 14. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, et al (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A; 100(17): 9991-6.
    • 15. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med.; 346(25): 1937-47.
    • 16. Lenz G, Staudt LM (2010) Mechanisms of Disease: Aggressive lymphomas. N Engl J Med. 362(15): 1417-29.
    • 17. Rutgen BC, Hammer SE, Gerner W, Christian M, de Arespacochaga AG, et al (2010) Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk Res. 34(7): 932-8.
    • 18. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, et al. (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large Bcell lymphoma. Nature.; 459(7247): 717-21.
    • 19. Gatto L, Yaqcaffy (2010) Available from: http://bioconductor.org/packages/ release/bioc/html/yaqcaffy.html (cited and accessed 20 October 2010).
    • 20. Parman C, Halling C, Gentleman R, affyQCReport (2010) Available from: http://www.bioconductor.org/packages/release/bioc/html/affyQCReport. html (cited and accesses 20 October 2010).
    • 21. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol.; 5(10): R80.
    • 22. The R Project for Statistical Computing (2010) Available from: http://www.rproject.org [cited and accessed 20 October 2010].
    • 23. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics.; 4(2): 249-64.
    • 24. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res.; 31(4): e15.
    • 25. NetAffx Analysis Center (2010) Available from: http://www.affymetrix.com/ analysis/index.affx [cited 2010 and Accessed August 2010).
    • 26. Partek (2010) PartekH Genomics SuiteTM Revision 6.5 ed. St. Louis: Partek Inc.
    • 27. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc.; 4(1): 44-57.
    • 28. Bolstad B affy (2009) 1.22.1 ed: http://bioconductor.org; (Accessed October 2010).
    • 29. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, et al. (2007) Integration of biological networks and gene expression data using Cytoscape. Nat Protoc.; 2(10): 2366-82.
    • 30. Bader GD, Hogue CW (2003) An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics.; 4: 2.
    • 31. Ingenuity (2010) Ingenuity Pathways Analysis. 8.7 ed. Redwood City, CA Ingenuity Systems Inc.
    • 32. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010 Jan 15;70(2):440-6.
    • 33. Jost PJ, Ruland J (2007) Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood; 109(7): 2700-7.
    • 34. Escarcega RO, Fuentes-Alexandro S, Garcia-Carrasco M, Gatica A, Zamora A (2007) The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol).; 19(2): 154-61.
    • 35. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature.; 441(7092): 431-6.
    • 36. Karin M (2008) The IkappaB kinase - a bridge between inflammation and cancer. Cell Res.; 18(3): 334-42.
    • 37. Thome M (2004) CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. Nat Rev Immunol.; 4(5): 348-59.
    • 38. Hiscott J, Kwon H, Genin P (2001) Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Invest.; 107(2): 143-51.
    • 39. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, et al (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 463(7277): 88-92.
    • 40. Brien G, Trescol-Biemont MC, Bonnefoy-Berard N (2007) Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene.; 26(39): 5828-32.
    • 41. Hollmann CA, Owens T, Nalbantoglu J, Hudson TJ, Sladek R (2006) Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40-mediated cell death. Cancer Res; 66(7): 3550-7.
    • 42. Paterson JC, Tedoldi S, Craxton A, Jones M, Hansmann ML, et al. (2006) The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas. Haematologica.; 91(6): 772-80.
    • 43. Zamanian-Daryoush M, Mogensen TH, DiDonato JA, Williams BR (2000) NFkappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase. Mol Cell Biol.; 20(4): 1278-90.
    • 44. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, et al (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature. 470(7332): 115-9.
    • 45. Gaurnier-Hausser A, Patel R, Baldwin AS, May MJ, Mason NJ (2011) NEMOBinding Domain Peptide Inhibits Constitutive NF-kappa B Activity and Reduces Tumor Burden in a Canine Model of Relapsed, Refractory Diffuse Large B-Cell Lymphoma Clinical Cancer Research: 17: 14: 4661-4671.
    • 46. Matherly LH, Taub JW, Ravindranath Y, Proefke SA, Wong SC, et al. (1995) Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood.; 85(2): 500-9.
    • 47. Molina JR (2008) Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. IDrugs.; 11(7): 508-21.
    • 48. Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, et al. (2010) Predictive factors for anthracycline-based chemotherapy for human breast cancer. Breast Cancer. 17(2): 103-9.
    • 49. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, et al (2009) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood.; 114(17): 3533-7.
    • 50. Fang C, Xu W, Li JY (2010) A systematic review and meta-analysis of rituximabbased immunochemotherapy for subtypes of diffuse large B cell lymphoma. Ann Hematol. 89(11): 1107-13.
    • 51. Frantz AM, Sarver AL, Ito D, Phang TL, Karimpour-Fard A, et al (2013) Molecular Profiling Reveals Prognostically Significant Subtypes of Canine Lymphoma Vet Pathol, vol. 50 no. 4 693-703.
  • No similar publications.

Share - Bookmark

Cite this article